Basal cell carcinoma: infiltrative (syn. morphoeic; morphoeiform; sclerosing)

LAST UPDATED: Jan 21, 2026

Patient Information Leaflet
Link: Basal cell carcinoma

https://pcds.org.uk/patient-info-leaflets/basal-cell-carcinoma

Introduction

An infiltrative basal cell carcinoma (BCC) is a type of BCC in which malignant cell infiltrate the dermis in thin strands between collagen fibres, making tumour margins less clinically apparent. As a result of delayed presentation, a tendency to invade deeper tissues (sometimes muscles, nerves, and bones), and higher rates of incomplete excision, infiltrative lesions tend to be associated with greater morbidity than other subtypes of BCC. 

This chapter is set out as follows:


Clinical findings

Distribution

  • Most common on the head, especially the central face, and the upper trunk

Morphology

  • Slowly expanding
  • Tend to be more subtle than other BCC subtypes, often with ill-defined edges
  • Can be depressed and may have surface telangiectasia
  • Some present as a yellow-white waxy patch
  • More advanced lesions show ulceration, crusting and fibrosis
  • Firm to palpate  

Dermoscopic features (hover over terminologies for description)

  • Tend to have indistinct margins
     
  • Often white-pink structureless. Occasionally may see blue-grey clods or brown structures
     
  • Fine branching vessels; tending to have a narrower calibre than the typical arborising vessels of solid BCC (for more information on vessels refer to the chapter Vessel patterns in dermoscopy)
     
  • Sometimes a stellate pattern of vessels, shiny white lines, or skin folds radiates laterally
     
  • More advanced lesions may be ulcerated
     
  • Can be associated with other BCC subtypes in the same lesion; known as a mixed BCC

Clinical Images

Please refer to notes on image rights at bottom of the page with regards to individual image ownership.


Management

  • Infiltrative basal cell carcinomas of the head and neck should be referred urgently to Secondary Care
     
  • For more information refer to the related chapter Basal cell carcinoma - an overview

Disclaimer - the author PCDS cannot accept responsibility for any misleading or incorrect statements, and the management of individual patients remains the direct responsibility of the individual doctor. We do however hope that visitors to this site can contact us regarding comments that are considered misleading or incorrect so that we can continue to improve the site.

Image Rights - The PCDS would like to thank Dermatoweb, DermQuest (Galderma), and others who have contributed images. All named individuals and organisations maintain copyright for the relevant images.

Quick Links

The following pharmaceutical companies have had no involvement in the content of this website or in our conference programmes

Almirall
Galderma
Glenmark
Johnson & Johnson
La Roche-Posay
LEO Pharma
Pierre Fabre
Schuco